Nyxoah S.A.
NASDAQ:NYXHMedical - Instruments & Supplies
+$0.02 today
- Market cap
- $87.89M
- Beta
- 0.89
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$1.99
Volume 0.17M
Average 0.22M
NYXH Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Nyxoah S.A.NASDAQ: NYXH
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of €16M (cash outflow) fell 28.5% year over year, behind the +24.9% change in trailing-twelve-month net income. Sequentially, it fell 31.9% from the prior quarter. Over 3 fiscal years it compounded at +44.2% a year.
Context
- Net income amounted to 898.7% of revenue in FY2025, down 349.5 pp from a year earlier.
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -€44.46M (-50.6%) for the fiscal year ending Dec 2026, a slowdown from the +59.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -€16M-31.9% QoQ
- Last fiscal yearDec 2025
- -€90.05M+59.6% YoY
- LTMMar 2026
- -€83.7M+24.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -28.5% | +116.2% | +144.7 pp |
| 1 year | +59.6% | -50.6% | -110.2 pp |
| 3-year CAGR | +44.2% | -44.5% | -88.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
EUR · from the cash flow
- Latest · FY2025
- (90.05M) EUR
- Year-over-year change
- -59.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (90.05M) | -59.6% |
| FY2024 | 2024-12-31 | (56.43M) | -26.4% |
| FY2023 | 2023-12-31 | (44.66M) | -48.6% |
| FY2022 | 2022-12-31 | (30.06M) | -22.0% |
| FY2021 | 2021-12-31 | (24.64M) | — |
Net Income vs competitors
How NYXH compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +24.9% is the 5th highest of 10, against a peer median of -11.4%.
- Net income amounts to 512.9% of revenue for NYXH, versus a peer median of 60.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $111.13M USD | +30.5% | +91.6% | 17982.7% | |
| LTM Mar 2026 | €83.7M EUR | +24.9% | +44.2% | 512.9% | |
| LTM Mar 2026 | $77.6M USD | -45.6% | -39.9% | 138.9% | |
| LTM Mar 2026 | $71.83M USD | +124.8% | -84.4% | 63.6% | |
| LTM Mar 2026 | $65.41M USD | +35.9% | -34.8% | 57.5% | |
| LTM Mar 2026 | $63.31M USD | +39.4% | -4.5% | — | |
| LTM Mar 2026 | $54.29M USD | -11.4% | +42.6% | 187.8% | |
| LTM Mar 2026 | $37.52M USD | -22.7% | +1.7% | 24.7% | |
| LTM Mar 2026 | $10.85M USD | -16.3% | -11.8% | 28.9% | |
| LTM Mar 2026 | $2.28M USD | -57.0% | -32.7% | 5.3% | |
| Peer median (excluding NYXH) | — | -11.4% | -11.8% | 60.5% | |
Competitors are the stored peer set for NYXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.64M) | (30.06M) | (44.66M) | (56.43M) | (90.05M) |
| Depreciation & Amortization | 1.66M | 1.93M | 2.36M | 2.72M | 4.48M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.27M | 2.7M | 2.61M | 3.97M | 0 |
| Change in Working Capital | (1.14M) | 86K | (3.49M) | 2.96M | 5.37M |
| Accounts Receivables | (2.52M) | 7K | (1.54M) | (751K) | (2.14M) |
| Inventory | (291K) | (536K) | (2.43M) | (1.4M) | 55.98K |
| Accounts Payables | 0 | 0 | 0 | 0 | 7.45M |
| Other Working Capital | 1.67M | 615K | 479K | 5.11M | 0 |
| Other Non-Cash Items | (2.49M) | (3.42M) | (1.6M) | (2.44M) | 12.7M |
| Operating Cash Flow | (25.34M) | (28.76M) | (44.78M) | (49.23M) | (67.5M) |
| Capital Expenditures | (11.82M) | (16.35M) | (10.96M) | (6.07M) | (804.7K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 3K |
| Purchases of Investments | 0 | (102.62M) | (80.02M) | (97.83M) | (42.03M) |
| Sales of Investments | 0 | 28.91M | 120.68M | 85.31M | 71.97M |
| Other Investing Activities | (10.35M) | (15.35M) | (6.15M) | (2.64M) | 0 |
| Investing Cash Flow | (11.82M) | (89.95M) | 32.01M | (16.33M) | 26.17M |
| Debt Repayment | (863K) | (1.07M) | (1.24M) | 8.48M | 21.19M |
| Common Stock Issued | 77.73M | 255K | 18.34M | 69.72M | 20.86M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (393K) | (167K) | (243K) | (758K) | (3.26M) |
| Financing Cash Flow | 76.47M | (983K) | 16.86M | 77.44M | 38.79M |
| Effect of Forex Changes | 3.89M | 2.06M | (369K) | 688K | 2.41M |
| Net Change in Cash | 43.21M | (117.62M) | 3.72M | 12.58M | (130.69K) |
| Free Cash Flow | (37.15M) | (45.11M) | (55.74M) | (55.3M) | (68.3M) |
Nyxoah S.A.
NASDAQ:NYXH
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.